Role of IL 12 and IL 23 as Potential Biomarkers in Diagnosis of Early Crohn's Disease

Tanta University110 enrolled

Overview

This study aims to evaluate the role of Interleukin (IL)-12 and IL-23 as potential biomarkers in the diagnosis of early Crohn's disease.

Crohn's disease (CD) is characterized by periods of remission and relapse, with symptoms ranging from abdominal pain and diarrhea to severe complications such as fistulas and intestinal obstruction. Interleukins (ILs) are known clusters of cytokines that regulate the proliferation, development, and activation of immune cells. IL-12 is predominantly a pro-inflammatory cytokine secreted by antigen-presenting cells (APC) in response to sensing of microbial components by Toll-like receptors. Another member of this family, IL-23 is also produced by DCs and macrophages after toll-like receptors (TLRs) engagement.

Study Type

OBSERVATIONAL

Enrollment

110

Conditions

Interleukin 12 Interleukin 23 Biomarker Diagnosis Crohn Disease

Interventions

Immunohistochemistry procedurePROCEDURE

Briefly, all slides will be rehydrated, and antigen retrieval will be performed using sodium citrate (pH = 6.0) in a pressure cooker (EDTA buffer, pH = 8.4). All slides will be blocked with endogenous peroxidase with 3% hydrogen peroxide and blocked non-specific protein with 2.5% bovine serum albumin in phosphate-buffered saline. If the result shows non-specific ileitis, immunohistochemical staining for IL-12 and IL-23 will be performed using sandwich enzyme-linked immunosorbent assays (ELISA).

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age from 18 to 65 years. * Both sexes. * Patients who are suspected of having Crohn's disease clinically and by colonoscopy (like ulcers, fistulas, or skip lesions). * Non-specific ileitis by histopathology. Exclusion Criteria: * Patients with no pathological samples through colonoscopy. * History of other significant gastrointestinal diseases (e.g., colon cancer, ischemic bowel disease). * Immunosuppressive therapy or biologic agents at the time of study. * Previous abdominal surgeries.

Locations (1)

Tanta University

Tanta, El-Gharbia, Egypt

Outcomes

Primary Outcomes

Sensitivity of IL-23 to predict Crohn's disease

Sensitivity of IL-23 to predict Crohn's disease will be recorded.

Time frame: 6 months after procedure

Secondary Outcomes

Sensitivity of IL-12 to predict Crohn's disease

Sensitivity of IL-12 to predict Crohn's disease will be recorded.

Time frame: 6 months after procedure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.